Pharmiweb
page: 1
next
Results 1 to 30Acticor Biotech Announces the Appointment of Patricia Zilliox to the Board of Directors as an Independent Director
2023-02-06, 20:46PARIS--(BUSINESS WIRE)--Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, is announcing today the appointment of...
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
2023-02-06, 20:46Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers) LYON, France--(BUSINESS WIRE)--$MAAT--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome...
SYNLAB AG: SYNLAB reports trading update for FY 2022 and revises FY 2023 guidance from lower COVID-19 testing
2023-02-06, 20:28EQS-News: SYNLAB AG / Key word(s): Change in Forecast SYNLAB AG: SYNLAB reports trading update for FY 2022 and revises FY 2023 guidance from lower COVID-19 testing 06.02.2023 / 20:40 CET/CEST The issuer is solely responsible for the content of this announcement. FY 2022 revenue anticipated to...
SYNLAB AG: SYNLAB revises FY 2023 guidance from lower COVID-19 testing volumes
2023-02-06, 20:28SYNLAB AG / Key word(s): Change in Forecast SYNLAB AG: SYNLAB revises FY 2023 guidance from lower COVID-19 testing volumes 06-Feb-2023 / 20:36 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG....
Qosina Appoints Lee Pochter as Executive Vice President
2023-02-06, 18:57RONKONKOMA, N.Y.--(BUSINESS WIRE)--#executivevicepresident--Qosina Corp., a leading global supplier of OEM single-use components to the medical and biopharmaceutical industries, is pleased to announce the appointment of Lee Pochter as Executive Vice President. Pochter brings more than 20 years of...
ZS to Acquire Intelligent Study Design Company Trials.ai
2023-02-06, 17:27ZS | Trials.ai solution leverages AI, tech and deep expertise for smarter study design, optimized participant experience and faster time to market. EVANSTON, Ill.--(BUSINESS WIRE)--Global management consulting and technology firm ZS announced today it has entered into a definitive agreement to...
IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy
2023-02-06, 17:27SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#clinicaltrials--IgGenix, Inc., a pre-clinical biotechnology company taking a revolutionary approach to directly address allergic disease, today announced its first close on a $40M Series B financing to advance its lead program in peanut allergy to the...
SDC Announces the Rollout of SDC Capture™ Solution
2023-02-06, 17:27SDC Capture™ creates optimized user experience for clients and sites, rapid deployment and robust data security BOSTON--(BUSINESS WIRE)--As the leading technology-enabled biometric CRO, SDC’s transformation to meet the needs of hybrid and decentralized trials of the future is based upon our...
Thompson Street Capital Partners Completes Growth Investment in Sabai Global
2023-02-06, 16:52ST. LOUIS--(BUSINESS WIRE)--Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today a growth investment in Sabai Global (“Sabai”), a Chesterfield, MO based provider of regulatory review and biosafety consulting services to pharmaceutical sponsors, CROs,...
Anodyne Nanotech, Inc. Appoints Jeff Mihm to its Board of Directors
2023-02-06, 16:52BOSTON--(BUSINESS WIRE)--Anodyne Nanotech, Inc., a venture-backed biotechnology company based in Boston and specializing in the transdermal delivery of biologics, announced today the appointment of Jeff Mihm as a member of its Board of Directors. Mr. Mihm previously served as the CEO of Noven...
Nutcracker Therapeutics Adds Dr. Thomas J. Dietz to Board of Directors
2023-02-06, 16:52EMERYVILLE, Calif.--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the appointment of Thomas J. Dietz, Ph.D., to the company’s board of directors. Dr. Dietz...
Concerto Biosciences Announces Strategic Business Development Hire
2023-02-06, 16:34Didier Vingadassalom, Ph.D., to Drive New Partnerships as Concerto's Senior Director, Business Development and Company’s First Employee Dedicated to Business Development CAMBRIDGE, Mass.--(BUSINESS WIRE)--Concerto Biosciences, a biotechnology company designing microbial communities that restore...
Orthopedic Trauma Devices Market is expected to be worth US$ 21.2 billion by 2033 | FMI Analyst
2023-02-06, 15:39The Orthopedic Trauma Devices Market is predicted to grow at a CAGR of 7.1% over the forecast period, according to FMI’s analysis. The industry’s estimated value is predicted to increase from US$ 10.7 Billion in 2023 to US$ 21.2 Billion by 2033. The market is poised to grow at a strong rate due to a...
Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men
2023-02-06, 15:39Prostate Screening EpiSwitch (PSE) blood test shows significant potential as an accurate and rapid cancer screening diagnostic High accuracy (94%), PPV (92%), and NPV (94%) reported in the high-impact, peer-reviewed journal Cancers Experts from Oxford BioDynamics, Imperial College London, University...
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer
2023-02-06, 15:39LONDON--(BUSINESS WIRE)--$SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the...
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2023-02-06, 15:39ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on January 31 , 2023 of a non-qualified stock option award to purchase an aggregate of 100,000 shares to Debora...
Pharma Veteran, Academician and Researcher Cristina Masseria, PhD, MSc to be Head of the Value and Evidence Team at AESARA
2023-02-06, 15:39CHAPEL HILL, N.C. & TORONTO & LONDON--(BUSINESS WIRE)--#HEOR--AESARA welcomes Cristina Masseria to AESARA bringing over 20 years of experience that spans across multiple therapy areas, research methods, innovation, and corporate leadership further expanding AESARA’s growth. Sissi Pham, CEO...
TransMed7, LLC Announces First Clinical Cases of Concorde Soft Tissue Biopsy Devices for Commercial Launch
2023-02-06, 15:39PORTOLA VALLEY, Calif.--(BUSINESS WIRE)--TransMed7, LLC announced today that the “First in Human” series of clinical cases using commercial production Concorde US devices (a member of the new Concorde family of vacuum-assisted, Single Insertion / Multiple Collection (SIMC®) Soft Tissue Biopsy...
Supply Chain Integrity, Transparency and Trust in the Pharmaceutical Industry
2023-02-06, 15:39Author Company: RKVST Author Name: Jon Geater, Chief Technology Officer Author Website: https://www.rkvst.com/ What is SCITT? While it may be yet another term you might not have heard of, it’s sure to become more familiar to pharmaceutical industry players as we strive to ensure traceability,...
Oxford University scientists’ AI diagnostic test accurately identifies known respiratory viruses in minutes
2023-02-06, 15:21Breakthrough in diagnostics testing enables ‘facial recognition for germs’ Collaboration with John Radcliffe Hospital used AI to identify respiratory viruses and different strains with an accuracy of >97% in under five minutes Founders seek further investment to help revolutionise...
Endogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa
2023-02-06, 15:21San Francisco, USA; Toronto, Canada; Zürich, Switzerland, February 6, 2023 Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous regenerative medicines, announced today that the US Food and Drug Administration (FDA) has designated the investigation of...
Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline
2023-02-06, 15:21Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies Single-target license with upfront and milestone payments plus royalties First Synaffix partnership announced with a Korean company THE NETHERLANDS and SOUTH KOREA, 6 February 2023 — Synaffix B.V., a biotechnology...
iotaSciences Launches New isoPick™ Single-Cell Picker to Further Expand Handling Solutions for Efficient Cell Biology & Gene Therapy Applications
2023-02-06, 15:21OXFORD, UK, February 06, 2023 / B3C newswire / -- iotaSciences, a spin-out from Oxford University in the field of single-cell handling solutions announced today product development completion for its newly built single cell picker instrumentation isoPick™. isoPick™ represents a powerful addition to...
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
2023-02-06, 15:21Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc....
Things To Consider If You Want A New Career In Pharmaceuticals Or Life Sciences
2023-02-06, 15:03Author Company: Tribe And Seek Author Name: Naomi Rothwell-Boyd Author Website: https://www.tribeandseek.com/ If you are looking to break into the field of pharmaceuticals or life sciences, there are a few things to consider that can help make the transition a success. Pharmaceuticals and life...
Profile of Sensoria Health: An Innovator in Wearable Medical Devices for Fitness and Health Care - ResearchAndMarkets.com
2023-02-06, 14:27DUBLIN--(BUSINESS WIRE)--The "Profile of Sensoria Health: An Innovator in Wearable Medical Devices for Fitness and Health Care" company profile from Textiles Intelligence Ltd. has been added to ResearchAndMarkets.com's offering. Sensoria Health, headquartered in Redmond, Washington, USA, is a...
Slingshot Biosciences Announces $11 Million in Series A3 Financing
2023-02-06, 14:27Developing synthetic cells for a range of applications in diagnostics and therapeutics EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, a biotechnology company building the world’s first on-demand synthetic cell platform for customizing cell and cell line mimics, today announced the...
Data Integrity and Document Management Training Course: Latest MHRA Data Integrity Guide and EMA TMF Guidelines (April 21, 2023) - ResearchAndMarkets.com
2023-02-06, 12:57DUBLIN--(BUSINESS WIRE)--The "Data Integrity and Document Management Training Course" conference has been added to ResearchAndMarkets.com's offering. This concise course covers the background to data integrity, why it is important and how its requirements affect both paper-based and computer-based...
IgA Nephropathy Market is expected to reach a valuation of US$ 85 Billion by 2033 | FMI
2023-02-06, 11:08During the forecast period 2023-2033, the IgA Nephropathy Market is expected to grow at a value of 7.5% CAGR, according to Future Market Insights. By the year 2033, the global market for IgA nephropathy is expected to rise up to a market valuation of US$ 85 Billion. Key factors such as high...
Trimethoprim is expected to capture 40% of the Chronic Granulomatous Disease Market | FMI study
2023-02-06, 11:08During the forecast period 2023-2033, the Chronic Granulomatous Disease (CGD) Management Market is expected to grow at a value of 4.9% CAGR, according to Future Market Insights. By the year 2033, the global market for Chronic Granulomatous disease (CGD) management is expected to rise up to a market...
- 1
2 3 Next page »